Who
We Are
Oruka is our name and our mission—derived from or, for “skin,” and arukah, for “restoration.” We are seasoned biopharma professionals and drug developers committed to improving the experiences of people living with plaque psoriasis, psoriatic arthritis, and other dermatologic and inflammatory indications.
Our
Pipeline
We are advancing potentially best-in-class monoclonal antibodies designed to set a new treatment standard for psoriasis and other related diseases by delivering higher rates of complete disease clearance with as few as one or two doses per year. Learn more about our EVERLAST-A Phase 2a trial of ORKA-001 in moderate-to-severe plaque psoriasis below.
Latest
News
Join Us
We seek passionate people to help us bring healthy skin within reach for those living with chronic disorders.